US to increase COVID-19 vaccine production for domestic and global use

The White House announced that it will partner with US industry to produce an additional one billion doses of COVID-19 vaccines by the second half of 2022.  The vaccines will be produced for use both in the United States and overseas. The plan, estimated to cost several billion US dollars, will also invest in antiviral medications and rapid testing. 

The focus for vaccine manufacturing is on those companies that have the mRNA vaccine capabilities to increase capacity against future coronavirus variants and also to expand manufacturing capacity for the next pandemic. The cost of the plan is not yet final, but funding will come from the US$1.9 trillion American Rescue Plan signed by President Biden earlier in 2021.

News report - The New York Times